Fierce BioTech

JUNE 6, 2023

Accelerating the Development of Nucleic Acid Therapies at Harwell Science and Innovation Campus Harwell Campus offers rich opportunities for pioneering NAT technology on all fronts, and the campus is attracting biotechnology companies of all sizes – from Moderna to start-ups to Government research institutes and accelerators. Download here!

Science 52

Science Therapies Molecular Biology Government 52

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

OCTOBER 30, 2024

Organoids will play increasingly crucial roles not only in research and diagnostics, but also in therapies to restore and enhance the human body. He received his BS in physics and biology from the University of Chicago and his PhD in molecular biology from the University of Pennsylvania.

Treatment 105

Treatment Disease Clinical Trials Molecular Biology 105

Drug Target Review

FEBRUARY 19, 2024

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Broad Institute

OCTOBER 23, 2024

In recent years, genetic editing technologies and other gene therapy approaches have given scientists the ability to alter the genes inside living cells. This limits our ability to design gene therapies that only effect certain cell types in the human body." Chan School of Public Health. "By

Research 136

Research DNA Laboratories Molecular Biology 136

Drug Target Review

NOVEMBER 27, 2023

By directly interfering with the eIF4F complex, eFFECTOR’s STRIs provide a promising avenue for disrupting the core mechanisms of cancer, offering the potential to improve patient outcomes and overcome the limitations of traditional cancer therapies. Dr Worland has served on the board of directors of Tracon Pharmaceuticals, Inc.,

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

DrugBank

MAY 15, 2024

But as molecular biology has advanced, so too has our approach to finding new drugs. 5 This period also saw the rise of biologics in the 1980s, which have played a crucial role in modern therapies, particularly for diseases like cancer. This method was more about serendipity than science.

Small Molecule 81

Small Molecule Molecular Biology Drugs Disease 81

Alta Sciences

MARCH 1, 2024

Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. q: How can Altasciences support sponsors’ Gene Therapy Programs?

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. Organoids for cell therapy and drug discovery. Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation. Elsevier; 2020.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Broad Institute

JUNE 21, 2023

said Vamsi Mootha , senior author of the study, an institute member at the Broad, professor of systems biology and medicine at Harvard Medical School, and professor of molecular biology at Massachusetts General Hospital. Even with profound ataxia, these mice can still, under the correct therapeutic regimen, reverse course.”

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Target Review

MARCH 15, 2024

He has a post-doctorate in virology, viral pathogenesis, viral vector development, and vaccines evaluation from Harvard Medical School, and a PhD in virology/molecular biology. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. References Mistry RK, Kelsall E, Sou SN, et al. Biotechnol Prog. Epub 2017 Sep 7.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. In particular, Editas is known to be exploring tunable CRISPR-Cas9 systems for therapies has developed self-inactivating Cas9 adeno-associated virus vectors.

Research 52

Research RNA Molecular Biology Small Molecule 52

Broad Institute

AUGUST 16, 2023

Mootha said that insight could one day help improve mitochondrial replacement therapies, which aim to replace disease-causing mitochondrial DNA with DNA from a healthy donor.

DNA 98

DNA Molecular Biology Disease Regulations 98

FDA Law Blog: Drug Discovery

MAY 1, 2024

Most of all, we are excited to be working alongside someone who shares our passion to bring new therapies to those in need,” notes James E. Sarah graduated with a cum laude degree in Cell and Molecular Biology from Towson University, a M.P.H. Valentine, HPM Director. from the University of Maryland School of Law.

Drug Development 52

Drug Development Molecular Biology Compliance Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2022

. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. 25) in the journal Communications Biology.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

The Pharma Data

NOVEMBER 23, 2020

Two years after its founding, Legend Biotech tied up with Johnson & Johnson to develop the anti-BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel). Cilta-cel snagged Breakthrough Therapy Designation from the U.S. as a director of molecular biology. Zhu founded Genetastix Corporation, Inc.,

Government 52

Government Molecular Biology Regulations Laboratories 52

Drug Target Review

MAY 27, 2024

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? At a base-layer, Caris’ comprehensive molecular profiling that we perform for patients today can identify predictive biomarkers for current FDA-approved ADCs.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Broad Institute

JANUARY 30, 2024

He majored in biological chemistry at the University of Chicago and during his junior year, he had a fortuitous meeting with his academic advisor about finding a student research position that would let him dive more deeply into the molecular details of biological systems. A combined MD/PhD program offered both opportunities.

Hospitals 137

Hospitals Virus Medical Schools Science 137

Drug Target Review

JULY 1, 2024

Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? With a strong market entry strategy and continuous evidence generation, SRP-001 has the potential to transform pain therapy and meet the enormous unmet needs in this field. South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

Drug Target Review

AUGUST 29, 2023

I’m also excited about the possibilities of personalised medicine and more precise therapies tailored to individual patients as well as progress in equity of access to medical treatment and diversification of patients studied. We are in a golden age of biotech exemplified by the impact this sector has had during the pandemic.

Science 98

Science Disease Molecular Biology Therapies 98

The Pharma Data

MARCH 16, 2022

As Professor Patrick Cramer, Professor at the Max-Planck Institute for Multidisciplinary Sciences and Director of the Molecular Biology Department, emphasized in his congratulatory speech: “Kai Johnsson is a world-leading research scientist in chemical biology.

Cell Biology 52

Cell Biology Molecular Biology Science Laboratories 52

Drug Target Review

APRIL 8, 2024

How have recent advancements in immune checkpoint blockade therapy affected outcomes for primary NSCLC? Dr Govindan : Even though immunotherapy and chemotherapy given after surgery improve the overall survival, as Dr Cote said, many may not need those therapies and a good number of them recur despite post operative systemic therapies.

Hospitals 52

Hospitals Therapies Clinical Trials Molecular Biology 52

Drug Target Review

OCTOBER 25, 2024

Biomarkers are an essential advancement that will help determine risk for developing Alzheimer’s disease, diagnose the disease before symptoms have progressed significantly, predict how quickly patients may experience cognitive decline and evaluate how well new therapies are working. Progress in molecular biology and translational science.

Disease 59

Disease Clinical Trials Therapies Science 59

The Pharma Data

SEPTEMBER 15, 2020

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

NOVEMBER 18, 2021

Senior Vice President, Early Clinical Development, Hematology/ Oncology and Cell Therapy and San Francisco point head. “ Each point has a complete molecular biology core installation that allows companies to do trials on day one. A core part of our gospel is to encourage interdisciplinary collaborations and new approaches.

Molecular Biology 52

Molecular Biology Pharmaceuticals Laboratories Clinical Development 52

Drug Target Review

JUNE 11, 2024

When choosing my bachelor’s degree, the choice was between pursuing a career in biology or in computer science. Biology won that battle, and I pursued a bachelor’s and master’s degree in biochemistry and molecular biology.

Engineering 64

Engineering Science Molecular Biology Doctors 64

Codon

DECEMBER 17, 2023

Molecular biology, as the field came to be called 3 , pushed biology from an object of study, driven forward by gentleman scientists and precocious country clergymen, into a tool with which to solve urgent problems. At least six CAR-T cancer therapies have now garnered F.D.A.

Engineering 52

Engineering Molecular Biology Doctors DNA 52

Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. Having an interest in the emerging field of gene therapy, I did a brief postdoc with Richard Mulligan at the Whitehead Institute.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Pharma Data

JANUARY 4, 2021

. chPD1 will be used in the Company’s proprietary chimeric antigen receptor therapy (CAR-T) platform using gamma-delta T-cells (GD-T). Barber’s work will give Kiromic a significant acceleration in the clinical development of its therapy platform and an even more significant advantage over its competitors.

Therapies 40

Therapies Molecular Biology Immune Response Science 40

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. with full-year revenue of US$23.04

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

JANUARY 6, 2021

This is a landmark study in converting the power of lethal botulinum neurotoxins into therapies. About CytoDel CytoDel is a privately held biopharmaceutical company that uses the tools of 21st century molecular biology to produce recombinant derivatives of botulinum neurotoxin customized to specific applications.

Science 52

Science Molecular Biology Treatment Production 52

Codon

JUNE 26, 2023

Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. Nevertheless, phage therapy did have a stint in the U.S. I’ll post an update soon. coli in mice.

DNA 52

DNA Therapies Engineering Clinical Trials 52

Codon

JUNE 26, 2023

Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. Nevertheless, phage therapy did have a stint in the U.S. I’ll post an update soon. coli in mice.

DNA 52

DNA Therapies Engineering Clinical Trials 52